MedPath Search

Found 538913 clinical trials

Sort by:

Comparing How Burn Wounds and Scars Heal in Children Using Chitosan and Silver Dressings

Not Applicable

Not yet recruiting

Conditions: Burns Degree Second
Pediatric

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Miloš Potkonjak

Target Recruit Count: 40

Registration Number: NCT06987981

Locations: 🇸🇮
General Hospital Novo mesto, Novo mesto, Slovenia

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

Phase 2

Not yet recruiting

Conditions: Hepatic Encephalopathy
Acute on Chronic Liver Failure (ACLF)
Decompensated Cirrhosis

Interventions: Drug: VS-01 on top of SOC (Active Treatment Group)
Drug: SOC

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Versantis AG

Target Recruit Count: 24

Registration Number: NCT06987968

Efficacy of Paraffin Bath and Peloidotherapy in Carpal Tunnel Syndrome

Not Applicable

Conditions: Carpal Tunnel Syndrome (CTS)
Peloidotherapy
Paraffin Bath
Exercise

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Konya Beyhekim Training and Research Hospital

Target Recruit Count: 90

Registration Number: NCT06986668

Locations: 🇹🇷
Konya Beyhekim Training and Research Hospital, Konya, Turkey

Clinical Evaluation of Pit and Fissure Sealants

Completed

Conditions: Pit and Fissure Sealants

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Canan Bayraktar Nahir

Target Recruit Count: 63

Registration Number: NCT06987955

Locations: 🇹🇷
Tokat Gaziosmanapaş University, Tokat, Kaleardı, Turkey

Transverse Thoracic Plane Block, Midpoint Transverse Process Plane to Pleura Block and Erector Spinae Plane Block for Analgesia in Patients Undergoing Thoracoscopic Sympathectomy

Not Applicable

Not yet recruiting

Conditions: Transverse Thoracic Plane Block
Midpoint Transverse Process Plane to Pleura Block
Erector Spinae Plane Block
Analgesia
Thoracoscopic Sympathectomy

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT06987110

Locations: 🇪🇬
Tanta University, Tanta, El-Gharbia, Egypt

Awareness Program on Knowledge Regarding Prevention of Hypertensive Crisis

Not Applicable

Recruiting

Conditions: Hypertension

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Riphah International University

Target Recruit Count: 35

Registration Number: NCT06986746

Locations: 🇵🇰
Combined Military Hospitals, Tarbela, KPK, Pakistan

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

Phase 3

Not yet recruiting

Conditions: Obesity Disease

Interventions: Drug: Maridebart cafraglutide
Drug: Placebo

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Amgen

Target Recruit Count: 272

Registration Number: NCT06987695

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Early Phase 1

Not yet recruiting

Conditions: Relapsed or Refractory Plasma Cell Neoplasms

Interventions: Genetic: CAR19BCMA-T cells
Drug: fludarabine and cyclophosphamide

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Affiliated Hospital to Academy of Military Medical Sciences

Target Recruit Count: 20

Registration Number: NCT06986434

Locations: 🇨🇳
the Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China

Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients

Phase 2

Not yet recruiting

Conditions: Lung Cancer (NSCLC)

Interventions: Drug: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Target Recruit Count: 25

Registration Number: NCT06987734

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China, Shanghai, Shanghai, China

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Phase 2

Not yet recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Inebilizumab

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Amgen

Target Recruit Count: 15

Registration Number: NCT06987539